Royalty Pharma Reports Q4 and Full Year 2023 Results [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Announced transactions of up to $4.0 billion in 2023 Full year 2024 guidance: Portfolio Receipts of $2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year of 2023 and introduced full year 2024 guidance for Portfolio Receipts. “Royalty Pharma delivered outstanding results in 2023,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer. “We reported another year of strong growth in royalty receipts and deployed substantial capital in value-enhancing transactions, including our strongest year ever for synthetic royalty transactions. Furthermore, a number of positive clinical and regulatory milestones strengthened the outlook for our diversified royalty portfolio. Based on the strong fundamental tailwinds underpinning our business, our strong balance sheet and
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21 [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024GlobeNewswire
- Royalty Pharma Declares Second Quarter 2024 DividendGlobeNewswire
- Royalty Pharma plc (NASDAQ: RPRX) had its price target lowered by analysts at Bank of America Co. from $40.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
RPRX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RPRX's page on the SEC website